Innate Pharma S.A. (EPA:IPH)

Innate Pharma Statistics

Total Valuation

Innate Pharma has a market cap or net worth of EUR 111.99 million. The enterprise value is 100.25 million.

Market Cap	111.99M
Enterprise Value	100.25M

Important Dates

The last earnings date was Thursday, March 26, 2026.

Earnings Date	Mar 26, 2026
Ex-Dividend Date	n/a

Share Statistics

Innate Pharma has 93.79 million shares outstanding. The number of shares has increased by 10.54% in one year.

Current Share Class	93.79M
Shares Outstanding	93.79M
Shares Change (YoY)	+10.54%
Shares Change (QoQ)	+6.11%
Owned by Insiders (%)	0.96%
Owned by Institutions (%)	1.34%
Float	62.93M

Valuation Ratios

PE Ratio	n/a
Forward PE	1.26
PS Ratio	12.44
PB Ratio	-5.16
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-2.04
EV / Sales	11.13
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.90

Financial Position

The company has a current ratio of 1.27

Current Ratio	1.27
Quick Ratio	1.27
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-0.43
Interest Coverage	n/a

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-38.85%
Return on Invested Capital (ROIC)	-165.88%
Return on Capital Employed (ROCE)	-207.17%
Weighted Average Cost of Capital (WACC)	6.95%
Revenue Per Employee	55,245
Profits Per Employee	-301,699
Employee Count	174
Asset Turnover	0.10
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -29.74% in the last 52 weeks. The beta is 0.74, so Innate Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.74
52-Week Price Change	-29.74%
50-Day Moving Average	1.34
200-Day Moving Average	1.60
Relative Strength Index (RSI)	48.57
Average Volume (20 Days)	270,828

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Innate Pharma had revenue of EUR 9.01 million and -49.18 million in losses. Loss per share was -0.55.

Revenue	9.01M
Gross Profit	-34.62M
Operating Income	-54.01M
Pretax Income	-49.18M
Net Income	-49.18M
EBITDA	-52.63M
EBIT	-54.01M
Loss Per Share	-0.55

Balance Sheet

The company has 34.31 million in cash and 22.57 million in debt, with a net cash position of 11.74 million or 0.13 per share.

Cash & Cash Equivalents	34.31M
Total Debt	22.57M
Net Cash	11.74M
Net Cash Per Share	0.13
Equity (Book Value)	-21.70M
Book Value Per Share	-0.24
Working Capital	10.06M

Cash Flow

In the last 12 months, operating cash flow was -52.76 million and capital expenditures -140,000, giving a free cash flow of -52.90 million.

Operating Cash Flow	-52.76M
Capital Expenditures	-140,000
Depreciation & Amortization	1.38M
Net Borrowing	-8.91M
Free Cash Flow	-52.90M
FCF Per Share	-0.56

Margins

Gross Margin	n/a
Operating Margin	-599.77%
Pretax Margin	-546.11%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Innate Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.54%
Shareholder Yield	-10.54%
Earnings Yield	-43.91%
FCF Yield	-47.23%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Innate Pharma has an Altman Z-Score of -11.09 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-11.09
Piotroski F-Score	2